Previous 10 | Next 10 |
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / May 24, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical ...
2023-05-19 08:20:29 ET Lucy Scientific Discovery ( LSDI ) +43% . Farfetch Limited ( FTCH ) +22% Q1 earnings call release Greenland Technologies Holding ( GTEC ) +14% Q1 earnings call release Nabriva Therapeutics ( NBRV ) +11% . G...
2023-05-15 08:25:29 ET GSI Technology ( GSIT ) +210% . ARS Pharmaceuticals ( SPRY ) +78% . ImmunoPrecise Antibodies ( IPA ) +39% . AirSculpt Technologies ( AIRS ) +37% . Meihua International Medical Technologies ( MHUA ) +37% ...
2023-05-15 08:24:37 ET Athenex ( ATNX ) -60% after bankruptcy filing . Larimar Therapeutics ( LRMR ) -34% reports preliminary top-line data from phase 2 trial’s 25 mg cohort showing increases in frataxin levels in patients with Friedreich’s Ataxia...
2023-05-12 13:14:08 ET Gainers: GSI Technology ( GSIT ) +149% . ARS Pharmaceuticals ( SPRY ) +80% . Zapp Electric Vehicles Group Limited ( ZAPP ) +42% . AirSculpt Technologies ( AIRS ) +39% . Blue Bird Corporation ( BLBD ) +34% ....
Dermata Therapeutics Inc (NASDAQ: DRMA) is one today's most active stocks by volume. So far today, approximately 33.92M shares of Dermata Therapeutics Inc have been exchanged, as compared to an average 30-day volume of 4.43M shares. Dermata Therapeutics, Inc., a clinical-stage biotechnology co...
2023-05-12 10:03:10 ET Gainers: ARS Pharmaceuticals ( SPRY ) +77% . Dermata Therapeutics ( DRMA ) +63% . AirSculpt Technologies ( AIRS ) +27% . GlycoMimetics ( GLYC ) +14% . BioAtla ( BCAB ) +13% . Losers: Heron Thera...
2023-05-11 17:44:47 ET Dermata Therapeutics press release ( NASDAQ: DRMA ): Q1 GAAP EPS of -$2.27. As of March 31, 2023, Dermata had $8.8 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022. For further details see: Dermata Ther...
- Dermata raised $5 million gross proceeds from a public offering in March 2023 - - Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 - - FDA agreed that Dermata's chemistry, manufacturing, and control ("CMC") procedures support the initiation of Phase 3 studies o...
--News Direct-- Dermata Therapeutics chairman and CEO Gerald Proehl takes Proactive's Stephen Gunnion through the clinical-stage biotechnology company's pipeline of treatments focused on medical and aesthetic skin conditions. He says the company's lead candidate DMT310 will move into ...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...